Company / Net Income
BridgeBio Pharma, Inc. Net Income History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$732.9M
FY2025
5-year range
-$732.9M / -$288.6M
FY2021-FY2025
Trend
-34.9%
vs FY2024
Sector context
#205 of 216
Health Care
What the data says
Among 216 Health Care companies, BridgeBio Pharma, Inc. is in the bottom 5% for net income. Net Income has fluctuated over the past 9 years, ranging from -$733M in FY2025 to -$44M in FY2017.
Based on SEC 10-K filings.
-$733M in FY2025.
Declined from -$586M to -$733M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 216This company -$732.9M Sector average $454.1M
▼
-261.4% below sector average
Key checks
Key Insights
- In FY2025, net income decreased 34.9% year-over-year.
- Ranks #205 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$732.9M | -34.9% |
| FY2024 | -$543.3M | +7.4% |
| FY2023 | -$586.5M | -21.0% |
| FY2022 | -$484.7M | -67.9% |
| FY2021 | -$288.6M | +42.9% |
| FY2020 | -$505.5M | -75.2% |
| FY2019 | -$288.6M | -70.3% |
| FY2018 | -$169.5M | -286.6% |
| FY2017 | -$43.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026